Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALA: CSF viral suppression with atazanavir/ritonavir plus lamivudine dual therapy in HIV-1 infection
2014-000496-64Phase 4Completed
- Sponsor
- Bellvitge University Hospital
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atazanavir, ritonavir and lamivudine in Human immunodeficiency virus infection type 1, sponsored by Bellvitge University Hospital. Primary endpoint: Presence of HIV-1 RNA in cerebrospinal fluid after switch. Started Mar 2014; status: completed.
02
Drugs
atazanavirritonavirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-000496-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000496-64.